A Phase I Clinical Trial of Trametinib in Combination With TAS-102 in Patients With Chemotherapy-Resistant RAS-Mutated (PIK3CA/PTEN-Wild-Type) Metastatic Colorectal Cancer
Latest Information Update: 11 Apr 2024
Price :
$35 *
At a glance
- Drugs Tipiracil/trifluridine (Primary) ; Trametinib (Primary)
- Indications Colon cancer; Colorectal cancer; Rectal cancer
- Focus Adverse reactions
- 04 Apr 2024 Status changed from active, no longer recruiting to completed.
- 28 Mar 2023 Planned End Date changed from 23 Feb 2023 to 23 Dec 2023.
- 28 Mar 2023 Planned primary completion date changed from 23 Feb 2023 to 23 Dec 2023.